"In 2013, the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA) was enacted. PAHPRA contains key legal authorities to strengthen U.S. preparedness for public health emergencies involving CBRN [chemical, biological, radiological, nuclear] agents and emerging infectious disease threats. PAHPRA also codified many of the activities already ongoing at FDA under the MCMi [Medical Countermeasures Initiative] Program to foster the development and availability of MCMs [medical countermeasures] as well as created new authorities to enable FDA to more effectively support preparedness and response efforts. PAHPRA requires FDA to issue an annual report detailing its MCM activities. This report responds to that requirement for fiscal year (FY) 2018 (October 1, 2017 - September 30, 2018). FDA obligated $113.2 million in FY 2018 to support CBRN and pandemic influenza-related MCM activities. These resources comprised a combination of base funding and no-year funding."
U.S. Food and Drug Administration: http://www.fda.gov/